저인산혈성 구루병에 대한 임상적 고찰
Clinical Study of Hypophosphatemic Rickets
1
조회
0
다운로드
0
인용
0
참고문헌
초록
목 적 : 저인산혈성 구루병 환아의 임상상, 각종 혈액화학 검사 수치 및 방사선 검사 소견, 치료에 대한 반응 등을 살피고 효과적인 치료에 도움이 되는 정보를 얻고자 본 연구를 시행하였다.방 법 : 1983년 7월부터 2004년 2월까지 서울대학교병원 소아과에서 저인산혈성 구루병으로 진단받고 내과적인 치료를 받은 환아들의 의무기록지를 후향적으로 분석하였다.결 과 : 대상환자는 56명이었고, 남녀의 비는 1:3 이었다. 주소는 대부분 하지만곡과 저신장이었고, 혼자 걷기 시작하면서 발견된 경우가 가장 많았다. 진단시 평균연령은 5년 2개월 이었으며 12개월 이전에 진단 받은 경우는 없었다. 14명(25%)에서 가족력이 있었다. 진단받은 연령과 신장의 표준편차 점수는 통계적으로 의미있는 음의 상관관계가 있었다(r=-0.47, P=0.005). 생화학적검사에서 정상 혈청 칼슘, 혈청 인의 저하, alkaline phosphatase의 상승, 세뇨관에서 인산 재흡수의 감소 및 정상 범위의 1,25(OH)2D3 치를 보였다. 방사선 검사는 구루병에 합당하였다. 치료제로 Joulie 용액과 비타민 D 대사체를 복용하였다. 치료를 시작한 후 혈청 인과 alkaline phosphatase는 통계적으로 의미있는(P<0.05) 호전을 보였고, 방사선 검사는 구루병의 치유를 보였으나, 신장 표준편차 점수는 의미있는 변화를 보이지 않았다(P=0.224). 치료의 부작용으로 신석회화(34%), 부갑상선호르몬의 상승(77%), 고칼슘뇨증(46%) 등이 발생하였다. 16명이 절골술을 통한 변형의 교정을 시행하였고, 그 중 4명은 하지연장을 함께 시행하였다. 결 론:증상의 시작과 진단 사이에는 수 년간의 지연이 있었다. 조기치료가 환자의 예후에 가장 중요하므로, 가족력이 있는 경우 증상 발현 이전에 생화학적 검사로 조기 진단 및 치료를 하도록 해야 한다. 치료 중에는 정기적인 모니터링과 용량의 조절을 통해 합병증에 대처해야 한다.
Abstract
Purpose:Hypophosphatemic rickets is a hereditary disease, characterized by hypophosphatemia due to renal phosphate wasting, impaired renal production of 1,25-dihydroxyvitamin D3, rachitic bone deformities and impaired growth. The purpose of this study is to provide clinical profiles of patients with hypophosphatemic rickets in our hospital. Methods:Between July 1983 and February 2004, 56 patients were diagnosed as having hypophosphatemic rickets. The medical records of these patients were reviewed retrospectively. Clinical manifestations, family histories, laboratory data, treatment outcomes were described. Results:Fifty six patients were enrolled in this study. The average age at symptom onset and diagnosis were 20 months and 5 years respectively. Fourteen patients had family histories. The main clinical manifestations were bow legs and short stature. There was a significant negative correlation between the ages and the height z-scores at the time of diagnosis(r=-0.47, P=0.005). Initial laboratory data showed normocalcemia, hypophosphatemia, elevated serum alkaline phosphatase, decreased tubular reabsorption of phosphate and a normal range of 1,25-dihydroxyvitamin D3. Radiographic examinations of bone revealed fraying, widening and cupping of the metaphyseal ends. Treatment consisted of Joulie solution and vitamin D metabolites, and resulted in improved biochemical and radiographic findings. However, height z-scores remained essentially unchanged(P=0.224). Complications of treatment were frequently observed, including hyperparathyroidism, nephrocalcinosis, and hypercalciuria. Sixteen patients had corrective osteotomy and 4 of them underwent leg lengthening together. Conclusion:There was a gap of several years between the onset of symptoms and the diagnosis. Early treatment seems to be essential to growth. For the earlier treatment, the offsprings of affected parents should be followed up closely.
참고문헌 (25)
- Carpenter TO, "New perspectives on the biology and treatment of X-linked hypophosphatemic rickets.", 44, pp.443~466 (1997)
- DiMeglio LA, "Hypophosphatemic rickets", 2, pp.165~173 (2001)
- Brame LA, "Renal phosphate wasting disorders: clinical features and pathogenesis", 24, pp.39~47 (2004)
- Jan de Beur SM, "Molecular pathogenesis of hypophosphatemic rickets.", 87, pp.2467~2473 (2002)
- Latta K, "Therapeutics of X-linked hypophosphatemic rickets.", hisa(s), pp.744~8
- Hanna JD, "Renal Hypophosphatemic Rickets", 6, pp.533~540 (1997)
- Choi SM, "Clinical Study of Hypophosphatemic Rickets.", 32, pp.1057~1063 (1989)
- Choi Y, "Familial Hypophosphatemic Rickets", 25, pp.192~198 (1997)
- Walton RJ, "Nomogram for derivation of renal threshold phosphate concentration.1975", pp.309~10
- Guinard JP, "Laborotary investigations", pp.399~424 (2004), Lippincott Williams & Wilkins Co
- Avni FE, "Diagnostic Imaging", pp.449~473 (2004), Lippincott Williams & Wilkins Co
- Jonsson KB, "Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked Hypophosphatemia.", 348, pp.1656~1663 (2003)
- Bai XY, "The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.", 278, pp.9843~9849 (2003)
- Shimada T,, "Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.", 143, pp.3179~3182 (2002)
- Fukumoto S, "Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets", osteomalacia., 2001, pp.48, 603~610
- Ward LM, "Resolution of severe adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.", 34, pp.905~911 (2004)
- Sermet-Gaudelus I, "Hereditary hypophosphatemic rickets with hypercalciuria: report of a new kindred.", 88, pp.83~86 (2001)
- Cho HY, "A clinical and molecular genetic study of children with hypophosphatemic rickets.", pp.4~6 (2004)
- M？kitie O, "Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets.", 88, pp.3591~3597 (2003)
- M？kitie O, "Prolonged high-dose phosphate treatment :a risk factor for tertiary hyperparathyroidism in X- linked hypophosphatemic rickets.", 58, pp.163~168 (2003)
- Saggese G, "Hypophosphataemic rickets", 53, pp.57~60 (2000)
- Saggese G, "Long-term growth hormone treatment in children with renal hypophosphatemic rickets :effects on growth, mineral metabolism, and bone density", 127, pp.395~402 (1995)
- Baroncelli GI, "Effect of growth hormone treatment on final height and bone mineral density in children with X-linked hypophosphateic rickets.", 138, pp.236~243 (2001)
- Rohmiller MT, "The effect of osteotomy on bowing and height in children with X-linked hypophosphatemia.", 19, pp.114~118 (1999)
- Choi IH, "Deformity correction of knee and leg lengthening by Iliarov method in hypophosphatemic rickets outcomes and significance of serum phosphate level", 22, pp.626~631 (2002)